Director Chell Jeffrey W. received 61,600 Actinium Pharmaceuticals shares at $0 per share. The transaction leaves him with 61,600 shares and 92,400 derivative securities, giving investors disclosed ownership figures for both Equity and derivative interests tied to the director.
Key Highlights
- The award was recorded on September 2, 2026, under transaction code A.
- Chell Jeffrey W. held 61,600 shares after the transaction.
- His post-transaction holdings also included 92,400 derivative securities.
Director Chell Jeffrey W. was awarded 61,600 Actinium Pharmaceuticals, Inc. (AMEX: ATNM) shares at $0 per share.
Director Award Details The
transaction occurred on September 2, 2026, under SEC transaction code A. Chell Jeffrey W. held 61,600 Actinium Pharmaceuticals shares after the award. A separate award on the same date covered 92,400 derivative securities. His ownership following that transaction was 92,400 derivative securities. The disclosed awards cover both shares and derivative securities. The share award was priced at $0 per share.
FAQs
Q: How many Actinium Pharmaceuticals shares did Chell Jeffrey W. receive?
A: Actinium Pharmaceuticals awarded Director Chell Jeffrey W. 61,600 shares at $0 per share on September 2, 2026. He owned 61,600 shares afterward.
Q: What did the ATNM director award include?
A: The ATNM transaction included 61,600 shares and a separate award of 92,400 derivative securities. Both awards were recorded on September 2, 2026.
Q: What does Chell Jeffrey W. own after the transaction?
A: After the award, Chell Jeffrey W. owned 61,600 Actinium Pharmaceuticals shares. The filing also reported that he owned 92,400 derivative securities following the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.